Axa S.A. Chemo Centryx, Inc. Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $1.97 Million - $2.72 Million	-39,700 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$47.25 - $65.16 $368,550 - $508,248	-7,800 Reduced 16.42%	39,700 $2.46 Million
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $287,370 - $382,478	-6,200 Reduced 11.55%	47,500 $2.6 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $976,074 - $1.65 Million	25,300 Added 89.08%	53,700 $3.09 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $929,531 - $1.44 Million	28,400 New	28,400 $1.14 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.